Title
Functional remediation for patients with bipolar II disorder: Improvement of functioning and subsyndromal symptoms
Date Issued
01 January 2015
Access level
metadata only access
Resource Type
journal article
Author(s)
Solé B.
Bonnin C.M.
Mayoral M.
Amann B.L.
Torres I.
González-Pinto A.
Jimenez E.
Crespo J.M.
Colom F.
Tabarés-Seisdedos R.
Reinares M.
Ayuso-Mateos J.L.
Soria S.
Garcia-Portilla M.P.
Ibañez Á.
Vieta E.
Martinez-Aran A.
Torrent C.
Al-Halabi S.
Alonso-Lana S.
Anaya C.
Arango C.
Balanzá-Martínez V.
Barbeito S.
Bobes J.
Chiclana G.
Cerrillo E.
Correa P.
Custal N.
Fernández P.
Fernández M.
Fuentes-Durá I.
Galván G.
Isella S.
Landín-Romero R.
Menchón J.M.
Merchan-Naranjo J.
Ortiz-Gil J.
Pacchiarotti I.
Reyes R.
Rosa A.R.
Rapado M.
Rodao J.M.
Saiz P.A.
Sánchez-Moreno J.
Segura B.
Selva-Vera G.
Saiz-Ruiz J.
Soria V.
Subirá M.
Ugarte A.
Valle J.
Vega P.
Universidad de Alcalá
Publisher(s)
Elsevier B.V.
Abstract
Recently, Functional Remediation (FR) has proven to be effective in improving the functional outcome of euthymic bipolar patients. The aim of this study was to test the efficacy of the FR program in a subsample of euthymic bipolar II patients (BPII). A post-hoc analyses were undertaken using data of 53 BPII outpatients who had participated in a multicenter, rater-blind, randomized, controlled trial exploring the efficacy of FR (n=17) as compared with a Psychoeducation group (PSY) (n=19) and a treatment as usual control group (TAU n=17). The primary outcome variable was the functional improvement defined as the mean change in the Functioning Assessment Short Test (FAST) from baseline to endpoint after the intervention. Regarding the treatment effect, data reveal a significant functional improvement from baseline to endpoint, suggestive for an interaction between program pertinence and time (pre-post). Nevertheless, Tukey's post-hoc test only revealed a trend in favor of a better outcome for FR when compared to the other two groups. We also found an interaction between program pertinence and time when analysing the subdepressive symptoms, with BPII patients in FR showing a significant reduction when compared to the PSY group. Our results suggest that the FR appears to be effective in improving the overall functional outcome in BPII, as well as in reducing subdepressive symptoms.
Start page
257
End page
264
Volume
25
Issue
2
Language
English
OCDE Knowledge area
Neurología clínica Psiquiatría
Scopus EID
2-s2.0-84925968793
PubMed ID
Source
European Neuropsychopharmacology
ISSN of the container
0924977X
Source funding
Brain and Behavior Research Foundation
Sponsor(s)
The authors thank the support of the Esther Koplowitz Centre (CEK) and of the Spanish Ministry of Economy and Competitiveness , Instituto de Salud Carlos III , CIBERSAM , the Spanish Ministry of Education and the Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya to the Bipolar Disorders Group ( 2009 SGR 1022 ), the postdoctoral fellowship Beatriu de Pinós of the Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya and the COFUND program of the Marie Curie Actions, the 7th Framework Programme of the European Community for research and technological development. Dr. Anabel Martinez-Aran׳s project is supported in part by a 2013 NARSAD , Independent Investigator Grant from the Brain and Behavior Research Foundation . Dr. Crespo has served as a consultant or speaker for AstraZeneca, Bristol-Myers Squibb, Janssen, Eli Lilly, GlaxoSmithKline, Lundbeck, Novartis, Otsuka, Pfizer, Sanofi-Sinthelabo, and Wyatt and has received grant support from FIS, Health Ministry, Idibell Foundation, and CIBERSAM. Supported by an ETS grant from the Spanish Ministry of Economy and Competitiveness (PI080180 and PI08/90825, PI08/90327, PI08/90675, PI08/90224, PI08/90654, PI08/90189, PI08/90916, PI08/90416, PI08/90094) PN 2008–2011, Instituto de Salud Carlos III, Subdirección General de Evaluación y Fomento de la Investigación; Fondo Europeo de Desarrollo Regional. Unión Europea, “Una manera de hacer Europa”; CIBERSAM; and the Comissionat per a Universitats i Recerca del DIUE de la Generalitat de Catalunya (2009 SGR 1022 to the Bipolar Disorders Group) and with the support of the Esther Koplowitz Centre (CEK). Anabel Martinez-Aran׳s project is supported, in part, by a 2013 NARSAD, Independent Investigator Grant from the Brain and Behavior Research Foundation. Dr. González-Pinto has received grants from or served as consultant, adviser, or CME speaker for Almirall, AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Merck, Novartis, Otsuka, Pfizer, Sanofi-Aventis, Schering-Plough, and the Spanish Ministry of Science and Innovation (CIBERSAM).
Sources of information: Directorio de Producción Científica Scopus